StockNews.AI
AGEN
StockNews.AI
5 days

Agenus Announces Virtual Annual Shareholders Meeting

1. Agenus Annual Shareholders Meeting set for June 17, 2025, at 10:30 a.m. ET. 2. Meeting to be held virtually; registration starts at 10:15 a.m. ET. 3. Shareholders can vote if recorded by April 24, 2025. 4. Webcast available for live and replay access on the company's website. 5. Agenus focuses on immuno-oncology with multiple therapeutic agents in development.

3 mins saved
Full Article

FAQ

Why Neutral?

The announcement is standard; shareholder meetings rarely affect stock price directly. Historically, similar announcements typically lead to minimal price movement.

How important is it?

While the meeting details are necessary for shareholders, they lack significant news. Hence, the importance in financial terms is moderate.

Why No Impact?

The meeting is far in the future; immediate impacts are unlikely. Shareholder meetings usually do not drive volatility unless significant announcements are made.

Related Companies

N/A
- LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Date: Tuesday, June 17, 2025 Time: 10:30 a.m. ET A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2025. Voting Information: Shareholders of Agenus as of the April 24th, 2025, record date can vote. Alliance Advisors, Agenus’s proxy solicitor, can assist shareholders with voting at 844-202-6561 or AGEN@AllianceAdvisors.com. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. More News From Agenus Inc.

Related News